EG226601 Inhibitors
Gm4846, with a predicted function as an N,N-dimethylaniline monooxygenase, plays a vital role in xenobiotic metabolism and detoxification processes within the cell. This enzymatic activity suggests involvement in the oxidation of N,N-dimethylaniline, a common substrate for monooxygenases. Inhibition of Gm4846 can be achieved through various mechanisms, involving specific chemical compounds that either directly interfere with its enzymatic activity or indirectly modulate upstream pathways that regulate its expression and function. CYP2C8 and CYP2D6 inhibitors, such as Amodiaquine, Quinidine, and Quinine, directly impact Gm4846 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. PPAR-alpha and PPAR-gamma agonists, like Gemfibrozil and Pioglitazone, respectively, indirectly influence Gm4846 by modulating PPAR signaling pathways, leading to changes in downstream pathways and affecting Gm4846 expression.
These diverse mechanisms of inhibition underscore the intricate regulatory network in which Gm4846 operates, providing valuable insights into potential points of intervention for further exploration into the molecular intricacies governing cellular responses in xenobiotic metabolism. The study of Gm4846 and its inhibition unravels a complex landscape of enzymatic regulation, shedding light on the dynamic interplay of molecular pathways that shape cellular functions in the context of xenobiotic metabolism and detoxification.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Amodiaquine | 86-42-0 | sc-207282 | 10 mg | $342.00 | 1 | |
Amodiaquine, a CYP2C8 inhibitor, directly influences Gm4846 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2C8 by Amodiaquine leads to a reduction in Gm4846 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
Gemfibrozil, a PPAR-alpha agonist, indirectly influences Gm4846 by modulating the PPAR-alpha signaling pathway. Activation of PPAR-alpha by Gemfibrozil leads to changes in downstream pathways, influencing Gm4846 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Quinidine, a CYP2D6 inhibitor, directly influences Gm4846 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2D6 by Quinidine leads to a reduction in Gm4846 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Fenofibrate, a PPAR-alpha agonist, indirectly influences Gm4846 by modulating the PPAR-alpha signaling pathway. Activation of PPAR-alpha by Fenofibrate leads to changes in downstream pathways, influencing Gm4846 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Fluoxetine | 54910-89-3 | sc-279166 | 500 mg | $318.00 | 9 | |
Fluoxetine, a CYP2D6 inhibitor, directly influences Gm4846 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2D6 by Fluoxetine leads to a reduction in Gm4846 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $55.00 $125.00 | 13 | |
Pioglitazone, a PPAR-gamma agonist, indirectly influences Gm4846 by modulating the PPAR-gamma signaling pathway. Activation of PPAR-gamma by Pioglitazone leads to changes in downstream pathways, influencing Gm4846 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Quinine | 130-95-0 | sc-212616 sc-212616A sc-212616B sc-212616C sc-212616D | 1 g 5 g 10 g 25 g 50 g | $79.00 $104.00 $166.00 $354.00 $572.00 | 1 | |
Quinine, a CYP2C8 inhibitor, directly influences Gm4846 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2C8 by Quinine leads to a reduction in Gm4846 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $120.00 $326.00 $634.00 $947.00 $1259.00 | 38 | |
Rosiglitazone, a PPAR-gamma agonist, indirectly influences Gm4846 by modulating the PPAR-gamma signaling pathway. Activation of PPAR-gamma by Rosiglitazone leads to changes in downstream pathways, influencing Gm4846 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
Paroxetine | 61869-08-7 | sc-507527 | 1 g | $180.00 | ||
Paroxetine, a CYP2D6 inhibitor, directly influences Gm4846 by inhibiting the enzymatic activity of N,N-dimethylaniline monooxygenase. Inhibition of CYP2D6 by Paroxetine leads to a reduction in Gm4846 activity, impacting its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
Wy-14643, a PPAR-alpha agonist, indirectly influences Gm4846 by modulating the PPAR-alpha signaling pathway. Activation of PPAR-alpha by Wy-14643 leads to changes in downstream pathways, influencing Gm4846 expression and its predicted function in N,N-dimethylaniline monooxygenase activity. | ||||||